Pay in 4 interest-free payments of $7.20 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
T.HuangJ
Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United Kingdom
Prior authorizations: Insurance companies require BMI thresholds, records of previous compliance to lifestyle changes, or failed response to other treatments
Always add water slowly against the vial wall and swirl gently rather than shaking
In October 2023, Carmot reported supportive preliminary Phase 1 data showing pharmacokinetics compatible with once-daily oral dosing
US$ 21.12
US$ 27.91
US$ 28.16
US$ 23.75
